Aeterna Zentaris Inc. (NASDAQ: AEZS) announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE